BG101711A - Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activity - Google Patents
Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activityInfo
- Publication number
- BG101711A BG101711A BG101711A BG10171197A BG101711A BG 101711 A BG101711 A BG 101711A BG 101711 A BG101711 A BG 101711A BG 10171197 A BG10171197 A BG 10171197A BG 101711 A BG101711 A BG 101711A
- Authority
- BG
- Bulgaria
- Prior art keywords
- amides
- substituted
- antagonistic activity
- piperidine
- piperidine esters
- Prior art date
Links
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical class FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001408 amides Chemical class 0.000 title abstract 2
- 230000003042 antagnostic effect Effects 0.000 title 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003523 serotonin 4 antagonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT95MI000491A IT1275903B1 (it) | 1995-03-14 | 1995-03-14 | Esteri e ammidi della 1,4-piperidina disostituita |
| PCT/EP1996/000903 WO1996028424A1 (en) | 1995-03-14 | 1996-03-04 | Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG101711A true BG101711A (en) | 1998-02-27 |
Family
ID=11370883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG101711A BG101711A (en) | 1995-03-14 | 1997-07-01 | Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activity |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6002009A (hr) |
| EP (1) | EP0815080B1 (hr) |
| JP (1) | JP4021477B2 (hr) |
| KR (1) | KR19980702972A (hr) |
| AR (1) | AR002967A1 (hr) |
| AT (1) | ATE269304T1 (hr) |
| AU (1) | AU5101096A (hr) |
| BG (1) | BG101711A (hr) |
| BR (1) | BR9607347A (hr) |
| CA (1) | CA2209904C (hr) |
| CO (1) | CO4700521A1 (hr) |
| CZ (1) | CZ285997A3 (hr) |
| DE (1) | DE69632724T2 (hr) |
| EE (1) | EE9700202A (hr) |
| ES (1) | ES2224159T3 (hr) |
| HR (1) | HRP960116A2 (hr) |
| IL (1) | IL117446A0 (hr) |
| IT (1) | IT1275903B1 (hr) |
| NO (1) | NO974236D0 (hr) |
| NZ (1) | NZ303941A (hr) |
| PE (1) | PE7698A1 (hr) |
| PL (1) | PL322211A1 (hr) |
| SK (1) | SK121397A3 (hr) |
| TR (1) | TR199700948T1 (hr) |
| WO (1) | WO1996028424A1 (hr) |
| YU (1) | YU14196A (hr) |
| ZA (1) | ZA962009B (hr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2164151T3 (es) * | 1995-06-06 | 2002-02-16 | Pfizer | N-(indol-2-carbonil)glicinamidas sustituidas y derivados como inhibidores de la glucogeno fosforilasa. |
| AU7001796A (en) * | 1995-09-22 | 1997-04-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and medicinal use thereof |
| TW445263B (en) | 1996-02-29 | 2001-07-11 | Janssen Pharmaceutica Nv | Novel esters of 1,4-disubstituted piperidine derivatives |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| US6339087B1 (en) | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| TW570920B (en) | 1998-12-22 | 2004-01-11 | Janssen Pharmaceutica Nv | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
| GB0211230D0 (en) * | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
| PL1664036T3 (pl) * | 2003-09-03 | 2012-04-30 | Pfizer | Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4 |
| TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| US7728006B2 (en) * | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| TWI351282B (en) * | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| US7737163B2 (en) * | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| AP2418A (en) * | 2004-06-15 | 2012-06-04 | Pfizer | Benzimidazolone carboxylic acid derivatives. |
| WO2005123718A2 (en) * | 2004-06-15 | 2005-12-29 | Pfizer Japan Inc. | Benzimidazolone carboxylic acid derivatives |
| JP2008509088A (ja) * | 2004-09-02 | 2008-03-27 | ファイザー株式会社 | ベンズイミダゾロンカルボン酸誘導体 |
| WO2006052640A1 (en) * | 2004-11-05 | 2006-05-18 | Theravance, Inc. | 5-ht4 receptor agonist compounds |
| EP1807423B1 (en) * | 2004-11-05 | 2009-05-20 | Theravance, Inc. | Quinolinone-carboxamide compounds |
| US7419989B2 (en) * | 2004-12-22 | 2008-09-02 | Theravance, Inc. | Indazole-carboxamide compounds |
| JP4130220B1 (ja) * | 2005-02-22 | 2008-08-06 | ファイザー株式会社 | ５ｈｔ４受容体アゴニストとしてのオキシインドール誘導体 |
| MX2007010769A (es) * | 2005-03-02 | 2008-03-07 | Theravance Inc | Compuestos de quinolina como agonistas de receptor 5-ht4. |
| JP5086248B2 (ja) * | 2005-06-07 | 2012-11-28 | セラヴァンス， インコーポレーテッド | ５−ｈｔ４受容体アゴニストとしてのベンゾイミダゾロン−カルボキサミド化合物 |
| MY143574A (en) * | 2005-11-22 | 2011-05-31 | Theravance Inc | Carbamate compounds as 5-ht4 receptor agonists |
| US8642772B2 (en) * | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| US8232315B2 (en) * | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| CN102781436B (zh) | 2009-11-06 | 2014-01-08 | 爱思开生物制药株式会社 | 纤维肌痛综合征的治疗方法 |
| JP5836280B2 (ja) | 2009-11-06 | 2015-12-24 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 注意欠陥／多動性障害（ａｄｈｄ）の治療方法 |
| NZ604423A (en) | 2010-06-24 | 2015-01-30 | Alkermes Pharma Ireland Ltd | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103862D0 (en) * | 1991-02-25 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
| GB9204565D0 (en) * | 1992-03-03 | 1992-04-15 | Smithkline Beecham Plc | Pharmaceuticals |
| JPH08502283A (ja) * | 1992-10-16 | 1996-03-12 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５−ｈｔ▲下４▼レセプターアンタゴニスト用の縮合環系ｎ−アルキルピペリジニル−４−メチルカルボン酸エステル／アミド |
| KR970702247A (ko) * | 1994-03-30 | 1997-05-13 | 고야 마사시 | 벤조산 화합물 및 이들의 약제로서의 용도(benzoic acid compound and use thereof as medicine) |
-
1995
- 1995-03-14 IT IT95MI000491A patent/IT1275903B1/it active IP Right Grant
-
1996
- 1996-03-04 NZ NZ303941A patent/NZ303941A/en unknown
- 1996-03-04 JP JP52723396A patent/JP4021477B2/ja not_active Expired - Lifetime
- 1996-03-04 BR BR9607347A patent/BR9607347A/pt not_active Application Discontinuation
- 1996-03-04 EE EE9700202A patent/EE9700202A/xx unknown
- 1996-03-04 AU AU51010/96A patent/AU5101096A/en not_active Abandoned
- 1996-03-04 DE DE69632724T patent/DE69632724T2/de not_active Expired - Lifetime
- 1996-03-04 SK SK1213-97A patent/SK121397A3/sk unknown
- 1996-03-04 KR KR1019970706380A patent/KR19980702972A/ko not_active Application Discontinuation
- 1996-03-04 WO PCT/EP1996/000903 patent/WO1996028424A1/en active IP Right Grant
- 1996-03-04 TR TR97/00948T patent/TR199700948T1/xx unknown
- 1996-03-04 AT AT96907342T patent/ATE269304T1/de active
- 1996-03-04 PL PL96322211A patent/PL322211A1/xx unknown
- 1996-03-04 EP EP96907342A patent/EP0815080B1/en not_active Expired - Lifetime
- 1996-03-04 ES ES96907342T patent/ES2224159T3/es not_active Expired - Lifetime
- 1996-03-04 CA CA002209904A patent/CA2209904C/en not_active Expired - Lifetime
- 1996-03-04 CZ CZ972859A patent/CZ285997A3/cs unknown
- 1996-03-04 US US08/913,425 patent/US6002009A/en not_active Expired - Lifetime
- 1996-03-05 PE PE1996000151A patent/PE7698A1/es not_active Application Discontinuation
- 1996-03-08 AR ARP960101670A patent/AR002967A1/es unknown
- 1996-03-11 YU YU14196A patent/YU14196A/sh unknown
- 1996-03-12 IL IL11744696A patent/IL117446A0/xx unknown
- 1996-03-13 CO CO96012408A patent/CO4700521A1/es unknown
- 1996-03-13 ZA ZA9602009A patent/ZA962009B/xx unknown
- 1996-03-13 HR HRMI95A000491A patent/HRP960116A2/hr not_active Application Discontinuation
-
1997
- 1997-07-01 BG BG101711A patent/BG101711A/xx unknown
- 1997-09-12 NO NO974236A patent/NO974236D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0815080A1 (en) | 1998-01-07 |
| ITMI950491A0 (it) | 1995-03-14 |
| JPH11501640A (ja) | 1999-02-09 |
| DE69632724T2 (de) | 2005-07-07 |
| KR19980702972A (ko) | 1998-09-05 |
| CA2209904C (en) | 2007-11-13 |
| TR199700948T1 (xx) | 1998-03-21 |
| EP0815080B1 (en) | 2004-06-16 |
| NO974236L (no) | 1997-09-12 |
| IL117446A0 (en) | 1996-07-23 |
| CO4700521A1 (es) | 1998-12-29 |
| DE69632724D1 (de) | 2004-07-22 |
| US6002009A (en) | 1999-12-14 |
| WO1996028424A1 (en) | 1996-09-19 |
| EE9700202A (et) | 1998-02-16 |
| AR002967A1 (es) | 1998-05-27 |
| YU14196A (sh) | 1999-03-04 |
| AU5101096A (en) | 1996-10-02 |
| NO974236D0 (no) | 1997-09-12 |
| CA2209904A1 (en) | 1996-09-19 |
| ITMI950491A1 (it) | 1996-09-14 |
| JP4021477B2 (ja) | 2007-12-12 |
| IT1275903B1 (it) | 1997-10-24 |
| ES2224159T3 (es) | 2005-03-01 |
| PL322211A1 (en) | 1998-01-19 |
| CZ285997A3 (cs) | 1998-02-18 |
| MX9706826A (es) | 1997-11-29 |
| PE7698A1 (es) | 1998-03-11 |
| ATE269304T1 (de) | 2004-07-15 |
| SK121397A3 (en) | 1998-02-04 |
| NZ303941A (en) | 1998-11-25 |
| HRP960116A2 (en) | 1997-10-31 |
| BR9607347A (pt) | 1997-12-30 |
| ZA962009B (en) | 1997-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG101711A (en) | Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activity | |
| HUT57202A (en) | Process for producing new pharmaceutically active 5-fluoro-2-///4-/cyclopropyl-methoxy/-2-pyridinyl/-methyl-sulfonyl/-1h-benzimidazol and pharmaceutical compositions containing them | |
| IL91768A0 (en) | Compounds being therapeutics for aids,their production and pharmaceutical compositions containing them | |
| HUT49592A (en) | Process for producing bis/hydroxymethyl/-cyclobutyl-purines and pyrimidines, as well as pharmaceutical compositions comprising same | |
| HUT53888A (en) | Fungicides comprising pyrimidine derivatives as active ingredient and process for producing the active ingredients | |
| AU7360887A (en) | Pharmacologically active 1,5-diarly-3-substituted- pyrazoles and method for synthesizing the same | |
| AU2227992A (en) | Conformationally restricted biologically active peptides, methods for their production and uses thereof | |
| IL119488A0 (en) | Substituted 2,4-imidazolidinediones their production and pharmaceutical compositions containing them | |
| HUT53362A (en) | Process for producing substituted 1,3-oxathiolans and pharmaceutical compositions comprising same | |
| AU8477891A (en) | Fibrinogen receptor antagonists | |
| HUP9800273A3 (en) | Benzothiazine dioxides as endothelin antagonists, process for their production and pharmaceutical compositions containing the same | |
| HUP0001165A3 (en) | Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists, pharmaceutical compositions containing them and process for producing them | |
| CA2064373A1 (en) | Piperidine derivatives | |
| MX9708394A (es) | Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion. | |
| HUT49370A (en) | Process for producing polypeptides and pharmaceutical compositions comprising same as active ingredient | |
| IL88927A0 (en) | Thienoazepines,their production and pharmaceutical compositions containing them | |
| HUT46660A (en) | Process for producing 3-alkoxy-2-amino-propyl-amines and pharmaceutical compositions comprising the same as active ingredient | |
| WO1990006943A3 (de) | Neue tnf-peptide | |
| AU657045B2 (en) | Tachykinin receptor antagonists, isoquinolones and their production | |
| AU5390294A (en) | Biologically active synthetic thyrotropin and cloned gene for producing same | |
| WO1993005807A3 (en) | Erythropoietin potentiating agents and methods for their use | |
| MY114693A (en) | Substituted benzenesulfonylureas and thioureas,processes for their preparation,their use for the production of pharmaceutical preparations, and pharmaceutical preparation containing them | |
| AU6272490A (en) | Biologically active compositions | |
| HUT58763A (en) | Process for producing reduced irreverzible bombezin antagonists and pharmaceutical compositions containing them as active components | |
| AU4119489A (en) | Microbiological process for producing agrochemically usable active ingredients |